Literature DB >> 781652

The pharmacology of tri-potassium di-citrato bismuthate (TDB).

T R Wilson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 781652

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


× No keyword cloud information.
  5 in total

1.  Bismuth subsalicylate reduces peptic injury of the oesophagus in rabbits.

Authors:  H P Tay; R C Chaparala; J W Harmon; J Huesken; N Saini; F Z Hakki; E J Schweitzer
Journal:  Gut       Date:  1990-01       Impact factor: 23.059

2.  Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents.

Authors:  C A McNulty; J Dent; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

3.  Tri-potassium di-citrato bismuthate: a report of its pharmacological properties and therapeutic efficacy in peptic ulcer.

Authors:  R N Brogden; R M Pinder; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976-12       Impact factor: 9.546

4.  Uptake and subcellular localisation of bismuth in the gastrointestinal mucosa of rats after short term administration of colloidal bismuth subcitrate.

Authors:  D Stiel; D J Murray; T J Peters
Journal:  Gut       Date:  1985-04       Impact factor: 23.059

5.  Oral tripotassium-dicitratobismuthate in gastric and duodenal ulceration. A double-blind controlled trial.

Authors:  S C Glover; J S Cantlay; J Weir; N A Mowat
Journal:  Dig Dis Sci       Date:  1983-01       Impact factor: 3.199
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.